biophBiomedical PhotonicsBiomedical Photonics2413-9432Non-profit partnership for development of domestic photodynamic therapy and photodiagnosis10.24931/2413-9432-2023-12-2-24-33bioph-592Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESЭкспериментальные исследования in vivo противоопухолевой эффективности фотодинамической и радиодинамической терапии, а также их сочетанияExperimental in vivo studies of the antitumor efficacy of photodynamic and radiodynamic therapy and their combinationsЦерковскийД. А.TzerkovskyD. A.

аг. Лесной

Lesnoy

tzerkovsky@mail.ruКозловскийД. И.KozlovskyD. A.

аг. Лесной

Lesnoy

МазуренкоА. Н.MazurenkoA. N.

аг. Лесной

Lesnoy

АдаменкоН. Д.AdamenkoN. D.

г. Витебск

Vitebsk

БоричевскийФ. Ф.BorichevskyF. F.

аг. Лесной

Lesnoy

Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. АлександроваБеларусьN.N. Alexandrov National Cancer Center of BelarusBelarusВитебский государственный университет им. П.М. МашероваБеларусьVitebsk State University named after P.M. MasherovBelarusМинская областная клиническая больницаБеларусьMinsk Regional Clinical HospitalBelarus20232108202312224–33Copyright © Церковский Д.А., Козловский Д.И., Мазуренко А.Н., Адаменко Н.Д., Боричевский Ф.Ф., 20232023Церковский Д.А., Козловский Д.И., Мазуренко А.Н., Адаменко Н.Д., Боричевский Ф.Ф.Tzerkovsky D.A., Kozlovsky D.A., Mazurenko A.N., Adamenko N.D., Borichevsky F.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pdt-journal.com/jour/article/view/592

В рамках пилотного исследования авторами изучена противоопухолевая эффективность фотодинамической терапии (ФДТ) в комбинации с радиодинамической терапией (РДТ) в эксперименте in vivo на подкожно перевитой опухолевой модели лимфосаркомы Плисса (ЛСП) у крыс. Фотосенсибилизатор (ФС) на основе хлорина е6 вводили внутривенно в дозе 2,5 мг/кг массы тела. Сеанс РДТ проводили на установке для контактной лучевой терапии (КЛТ) однократно через 2,5–3 ч после окончания введения ФС с использованием γ-излучения (192Ir) в разовой очаговой дозе 6 Гр. Сеанс ФДТ осуществляли однократно непосредственно после воздействия ионизирующим излучением с помощью полупроводникового лазера «PDT diode laser» (OOO «Imaf Axicon», Беларусь, λ=660±5 нм) со световой дозой 100 Дж/см2  с плотностью мощности 0,2 Вт/см2  и мощностью 0,353 Вт. Все крысы были разделены на 4 группы по 6–7 особей в каждой: интактный контроль (ИК), ФС + ФДТ, ФС + КЛТ, ФС + КЛТ + ФДТ. Критерии оценки противоопухолевой эффективности: средний объем опухолей (Vср., см3 ), коэффициент абсолютного прироста опухолей (К, в относительных единицах (ОЕ), показатель торможения роста опухолей (ТРО, %), частота полной регрессии опухоли (ПР, %), доля излеченных крыс (%), показатель увеличения продолжительности жизни (УПЖ, %). Различия считались статистически значимыми при уровне значимости p<0,05. На 18-е сутки эксперимента Vср. в группах составил 63,25±2,76 см³; 29,03±6,06 см³ (р=0,0002); 22,18±5,94 см³ (р<0,0001); 11,76±3,29 см³ (р=0,0000), соответственно. Коэффициенты К – 4516,86 ОЕ; 2638,09 ОЕ; 2024,45 ОЕ; 979,00 ОЕ. Показатель ТРО – 54,10% (ФС + ФДТ); 64,93% (ФС + КЛТ); 81,41% (ФС + КЛТ + ФДТ). Показатель УПЖ – 48,57% (ФС + ФДТ); 60,00% (ФС + КЛТ); 97,71% (ФС + КЛТ + ФДТ). На 60-е и 90-е сутки эксперимента частота ПР и доля излеченных крыс были одинаковыми и составили в группах 0%; 16,7%; 14,3% и 28,6%, соответственно. Полученные результаты свидетельствуют о перспективности и актуальности дальнейших исследований в данном научном направлении. 

The authors studied the antitumor efficacy of photodynamic therapy (PDT) in combination with radiodynamic therapy (RDT) in an in vivo experiment. The study was approved by the Ethics Committee of the N.N. Alexandrov National Cancer Center of Belarus (protocol dated February 25, 2022, № 180). The work was performed on 26 white non-linear rats weighing 200 ± 50 g. Pliss lymphosarcoma (PLS) was used as a tumor model, which was transplanted subcutaneously. Photosensitizer (PS) «Photolon» (RUE «Belmedpreparaty», Belarus) was administered intravenously at a dose of 2.5 mg/kg of body weight. The RDT session was performed by the contact method (CRT) once 2.5–3 times after the end of the infusion of the PS on the «microSelectron-HDR V3 Digital apparatus» (Elekta, Sweden) using γ-radiation (192Ir) in a single focal dose 6 Gy. A PDT session was performed once immediately after exposure to ionizing radiation using a «PDT diode laser» (LTD Imaf Axicon, Belarus, λ=660±5 nm) at an exposure dose of 100 J/cm2  with a power density of 0.2 W/cm2  and a power of 0.353 watts. All rats were divided into 4 groups of 6–7 animals each: intact control (IC), PS + PDT, PS + CRT, PS + CRT + PDT. The criteria for evaluating antitumor efficacy were: the average volume of tumors (Vav, cm3 ), the coefficient of absolute growth of tumors (K, in RU), the coefficient of tumor growth inhibition (TGI, %), the frequency of complete tumor regressions (CR, %), the proportion of cured rats (%), an increase in the average duration of dead rats (%). Differences were considered statistically significant at p<0.05. On the 18th day of the experiment, Vav. in groups was 63.25±2.76 cm³; 29.03±6.06 cm³ (p=0.0002); 22.18±5.94 cm³ (р<0.0001); 11.76±3.29 cm³ (p=0.0000), respectively. Coefficients K – 4516.86 RU; 2638.09 RU; 2024.45 RU; 979.00 RU. TGI coefficients – 54.10% (PS + PDT); 64.93% (PS + CRT); 81.41% (PS + CRT + PDT). An increase in the average duration of dead rats indicator – 48.57% (PS + PDT); 60.00% (PS + CRT); 97.71% (PS + CRT + PDT). On the 60th and 90th days of the experiment, the frequency of PR and the proportion of cured rats were the same and amounted to 0%; 16.7%; 14.3%, and 28.6%, respectively. The results obtained indicate the prospects and relevance of further research in this scientific direction.

экспериментальное исследованиекрысыперевивные опухолифотодинамическая терапиярадиодинамическая терапияфотосенсибилизаторexperimental researchratstransplanted tumorsphotodynamic therapyradiodynamic therapyphotosensitizerReferencesYanovsky R.L., Bartenstein D.W., Rogers G.S., Isakoff S.J., Chenet S.T. Photodynamic therapy for solid tumors: A review of the literature. Photodermatol. Photoimmunol. Photomed, 2019, vol. 35, рр. 295-303. doi: 10.1111/phpp.12489.Yanovsky R.L., Bartenstein D.W., Rogers G.S., Isakoff S.J., Chenet S.T. Photodynamic therapy for solid tumors: A review of the literature // Photodermatol. Photoimmunol. Photomed. – 2019. – Vol. 35. – P. 295-303. doi: 10.1111/phpp.12489.Gunaydin G., Gedik M.E., Ayan S. Photodynamic therapy for the treatment and diagnosis of cancer – a review of the current clinical status. Front. Chem, 2021, vol. 9, рр. e686303. doi:10.3389/fchem.2021.686303.Gunaydin G., Gedik M.E., Ayan S. Photodynamic therapy for the treatment and diagnosis of cancer – a review of the current clinical status // Front. Chem. 2021. – Vol. 9. – P. e686303. doi:10.3389/fchem.2021.686303.Castano А.P., Mroz P., Hamblin M.R. Photodynamic therapy and anti-tumour immunity. Nature Reviews Cancer, 2006, vol. 6(7), рр. 535-545. doi: 10.1038/nrc1894.Castano А.P., Mroz P., Hamblin M.R. Photodynamic therapy and anti-tumour immunity // Nature Reviews Cancer. – 2006. – Vol. 6(7). – P. 535-545. doi: 10.1038/nrc1894.Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., Korbelik M., Moan J., Mroz P., Nowis D., Piette J., Wilson B.C., Golab J. Photodynamic therapy of cancer: an update. CA-A Cancer J. Clin, 2011, vol. 61(4), рр. 250-281. doi: 10.3322/caac.20114.Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., Korbelik M., Moan J., Mroz P., Nowis D., Piette J., Wilson B.C., Golab J. Photodynamic therapy of cancer: an update // CA-A Cancer J. Clin. – 2011. – Vol. 61(4). – P. 250-281. doi: 10.3322/caac.20114.Correia J.H., Rodrigues J.A., Pimenta S., Dong T., Yang Z. Photodynamic therapy review: principles, photosensitizers, applications, and future directions. Pharmaceutics, 2021, vol. 13, р. e1332. doi:10.3390/pharmaceutics13091332.Correia J.H., Rodrigues J.A., Pimenta S., Dong T., Yang Z. Photodynamic therapy review: principles, photosensitizers, applications, and future directions // Pharmaceutics. – 2021. – Vol. 13. – P. e1332. doi:10.3390/pharmaceutics13091332.Yang M., Yang T., Mao C. Enhancement of photodynamic cancer therapy by physical and chemical factors. Angew Chem Int Ed Engl, 2019, vol. 58(40), рр. 14066-14080. doi:10.1002/anie.201814098.Yang M., Yang T., Mao C. Enhancement of photodynamic cancer therapy by physical and chemical factors // Angew Chem Int Ed Engl. – 2019. – Vol. 58(40). – P. 14066-14080. doi:10.1002/anie.201814098.Hu H., Feng W., Qian X., Yu L., Chen Y., Li Y. Emerging nanomedicine-enabled/enhanced nanodynamic therapies beyond traditional photodynamics. Adv. Mater, 2021, vol. 33(12), р. e2005062. doi: 10.1002/adma.202005062.Hu H., Feng W., Qian X., Yu L., Chen Y., Li Y. Emerging nanomedicine-enabled/enhanced nanodynamic therapies beyond traditional photodynamics. // Adv. Mater. – 2021. – Vol. 33(12). – P. e2005062. doi: 10.1002/adma.202005062.Rodrigues J.A., Correia J.H. Enhanced photodynamic therapy: a review of combined energy sources. Cells, 2022, vol. 11(24), р. 3995. doi: 10.3390/cells11243995.Rodrigues J.A., Correia J.H. Enhanced photodynamic therapy: a review of combined energy sources // Cells. – 2022. – Vol. 11(24). – P. 3995. doi: 10.3390/cells11243995.Larue L., Mihoub A.B., Youssef Z., Colombeau L., Acherar S., André J.C., Arnoux P., Baros F., Vermandel M., Frochot C. Using X-rays in photodynamic therapy: an overview. Photochem. Photobiol. Sci, 2018, vol. 17(11), рр. 1612-1650. doi: 10.1039/c8pp00112j.Larue L., Mihoub A.B., Youssef Z., Colombeau L., Acherar S., André J.C., Arnoux P., Baros F., Vermandel M., Frochot C. Using X-rays in photodynamic therapy: an overview // Photochem. Photobiol. Sci. – 2018. – Vol. 17(11). – P. 1612-1650. doi: 10.1039/c8pp00112j.He L., Yu X., Li W. Recent progress and trends in X-ray-induced photodynamic therapy with low radiation doses. ACS Nano, 2022, vol. 16(12), рр. 19691-19721. doi: 10.1021/acsnano.2c07286.He L., Yu X., Li W. Recent progress and trends in X-ray-induced photodynamic therapy with low radiation doses // ACS Nano. – 2022. – Vol. 16(12). – P. 19691-19721. doi: 10.1021/acsnano.2c07286.Guidelines for the experimental (preclinical) study of new pharmacological substances / under the general editorship of the corresponding member of the Russian Academy of Medical Sciences prof. R. U. Khabrieva. – 2nd ed., reprint. and additional – M. : JSC “Publishing House «Medicine», 2005, pp. 647-649.Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ / под общ. ред. чл.- корр. РАМН проф. Р. У. Хабриева. – 2 изд., перераб. и доп. – М. : ОАО «Издательство «Медицина» . – 2005. – С. 647-649.Takahashi J., Nagasawa S., Doi M., Takahashi M., Narita Y., Yamamoto J., Ikemoto M.J., Iwahashi H. In vivo study of the efficacy and safety of 5-aminolevulinic radiodynamic therapy for glioblastoma fractionated radiotherapy. Int. J. Mol. Sci, 2021, vol. 22, рр. 1-15. doi:10.3390/ijms22189762.Takahashi J., Nagasawa S., Doi M., Takahashi M., Narita Y., Yamamoto J., Ikemoto M.J., Iwahashi H. In vivo study of the efficacy and safety of 5-aminolevulinic radiodynamic therapy for glioblastoma fractionated radiotherapy // Int. J. Mol. Sci. – 2021. – Vol. 22. – P. 1-15. doi:10.3390/ijms22189762.Kulka U., Schaffer M., Siefert A. Photofrin as a radiosensitizer in an in vitro cell survival assay. Biochem. Biophys. Res. Commun, 2003, vol. 311(1), рр. 98-103. doi: 10.1016/j.bbrc.2003.09.170.Kulka U., Schaffer M., Siefert A. Photofrin as a radiosensitizer in an in vitro cell survival assay // Biochem. Biophys. Res. Commun. – 2003. – Vol. 311(1). – P. 98-103. doi: 10.1016/j.bbrc.2003.09.170.Schaffer M., Kulka U., Ertl-Wagner B., Schaffer P.M., Friso E., Hell R., Jori G., Hofstetter A., Dühmke E. Effect of Photofrin II as a radiosensitizing agent in two different oesophageal carcinoma cell lines. J. Porphyrins Phthalocyanines, 2005, vol. 9, рр. 470-475. doi:10.1142/S1088424605000587.Schaffer M., Kulka U., Ertl-Wagner B., Schaffer P.M., Friso E., Hell R., Jori G., Hofstetter A., Dühmke E. Effect of Photofrin II as a radiosensitizing agent in two different oesophageal carcinoma cell lines // J. Porphyrins Phthalocyanines. – 2005. – Vol. 9. – P. 470-475. doi:10.1142/S1088424605000587.Benayoun L., Schaffer M., Bril R., Gingis-Velitski S., Segal E., Nevelsky A., Satchi-Fainaro R., Shaked Y. Рorfimer-sodium (Photofrin II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy. Cancer Biol. Ther, 2013, vol. 14(1), рр. 64-74. doi: 10.4161/cbt.22630.Benayoun L., Schaffer M., Bril R., Gingis-Velitski S., Segal E., Nevelsky A., Satchi-Fainaro R., Shaked Y. Рorfimer-sodium (Photofrin II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy // Cancer Biol. Ther. – 2013. – Vol. 14(1). – P. 64-74. doi: 10.4161/cbt.22630.Schaffer M., Schaffer P.M., Corti L., Gardiman M., Sotti G., Hofstetter A., Jori G., Dühmke E. Photofrin as a specific radiosensitizing agent for tumors: studies in comparison to other porphyrins, in an experimental in vivo model. J. Photochem. Photobiol. B: Biol, 2002, vol. 66, рр. 157-164. doi: 10.1016/s1011-1344(02)00237-3.Schaffer M., Schaffer P.M., Corti L., Gardiman M., Sotti G., Hofstetter A., Jori G., Dühmke E. Photofrin as a specific radiosensitizing agent for tumors: studies in comparison to other porphyrins, in an experimental in vivo model // J. Photochem. Photobiol. B: Biol. – 2002. – Vol. 66. – P. 157-164. doi: 10.1016/s1011-1344(02)00237-3.Rutkovskienė L., Plėšnienė L., Sendiulienė D., Stančius A., Liutkevičiūtė-Navickienė J. Sensitization of rat C6 glioma cells to ionizing radiation by porphyrins. Acta Medica Lituan, 2011, vol. 18(2), рр. 56-62. doi:10.6001/actamedica.v18i2.1816.Rutkovskienė L., Plėšnienė L., Sendiulienė D., Stančius A., Liutkevičiūtė-Navickienė J. Sensitization of rat C6 glioma cells to ionizing radiation by porphyrins // Acta Medica Lituan. – 2011. – Vol. 18(2). – P. 56-62. doi:10.6001/actamedica.v18i2.1816.Yamamoto J., Ogura S.I., Tanaka T., Kitagawa T., Nakano Y., Saito T., Takahashi M., Akiba D., Nishizawa S. Radiosensitizing effect of 5-aminolevulinic acid-induced protoporphyrin IX in glioma cells in vitro. Oncology Rep, 2012, vol. 27, рр. 1748-1752. doi: 10.3892/or.2012.1699.Yamamoto J., Ogura S.I., Tanaka T., Kitagawa T., Nakano Y., Saito T., Takahashi M., Akiba D., Nishizawa S. Radiosensitizing effect of 5-aminolevulinic acid-induced protoporphyrin IX in glioma cells in vitro // Oncology Rep. – 2012. – Vol. 27. – P. 1748-1752. doi: 10.3892/or.2012.1699.Panetta J.V., Cvetkovic D., Chen X., Chen L., Charlie Ma C.M. Radiodynamic therapy using 15-MV radiation combined with 5-aminolevulinic acid and carbamide peroxide for prostate cancer in vivo. Phys. Med. Biol, 2020, vol. 65(16), рр. 1-14. doi:10.1088/1361-6560/ab9776.Panetta J.V., Cvetkovic D., Chen X., Chen L., Charlie Ma C.M. Radiodynamic therapy using 15-MV radiation combined with 5-aminolevulinic acid and carbamide peroxide for prostate cancer in vivo // Phys. Med. Biol. – 2020. – Vol. 65(16). – P. 1-14. doi:10.1088/1361-6560/ab9776.Yang D.M., Cvetkovic D., Chen L., Charlie Ma C.M. Therapeutic effects of in-vivo radiodynamic therapy (RDT) for lung cancer treatment: a combination of 15MV photons and 5-aminolevulinic acid (5-ALA). Biomed. Phys. Eng. Express, 2022, vol. 8(6), рр. 1-15. doi: 10.1088/2057-1976/ac9b5c.Yang D.M., Cvetkovic D., Chen L., Charlie Ma C.M. Therapeutic effects of in-vivo radiodynamic therapy (RDT) for lung cancer treatment: a combination of 15MV photons and 5-aminolevulinic acid (5-ALA) // Biomed. Phys. Eng. Express. – 2022. – Vol. 8(6). – P. 1-15. doi: 10.1088/2057-1976/ac9b5c.Matsuyama Y., Nakamura T., Yoshida K., Hagi T., Iino T., Asanuma K., Sudo A. Radiodynamic therapy with acridine orange local administration as a new treatment option for primary and secondary bone tumours. Bone Joint Res, 2022, vol. 11(10), рр. 715-722. doi: 10.1302/2046-3758.1110.BJR-2022-0105.R2.Matsuyama Y., Nakamura T., Yoshida K., Hagi T., Iino T., Asanuma K., Sudo A. Radiodynamic therapy with acridine orange local administration as a new treatment option for primary and secondary bone tumours // Bone Joint Res. – 2022. – Vol. 11(10). – P. 715-722. doi: 10.1302/2046-3758.1110.BJR-2022-0105.R2.Dupin C., Sutter J., Amintas S., Derieppe M.A., Lalanne M., Coulibaly S., Guyon J., Daubon T., Boutin J., Blouin J.M., Richard E., Moreau-Gaudry F., Bedel A., Vendrely V., Dabernat S. An orthotopic model of glioblastoma is resistant to radiodynamic therapy with 5-aminolevulinic acid. Cancers (Basel), 2022, vol. 14(17), р. 4244. 10.3390/cancers14174244.Dupin C., Sutter J., Amintas S., Derieppe M.A., Lalanne M., Coulibaly S., Guyon J., Daubon T., Boutin J., Blouin J.M., Richard E., Moreau-Gaudry F., Bedel A., Vendrely V., Dabernat S. An orthotopic model of glioblastoma is resistant to radiodynamic therapy with 5-aminolevulinic acid // Cancers (Basel). – 2022. – Vol. 14(17). – P. 4244. 10.3390/cancers14174244.ClinicalTrials.gov Identifier: NCT04381806.ClinicalTrials.gov Identifier: NCT04381806.ClinicalTrials.gov Identifier: NCT05590689.ClinicalTrials.gov Identifier: NCT05590689.Filonenko E.V., Ivanova-Radkevich V.I. Photodynamic therapy in the treatment of extramammary Paget disease. Biomedical Photonics, 2022, vol. 11(3), рр. 24-34. doi: 10.24931/2413–9432–2022–11-3-24–34Filonenko E.V., Ivanova-Radkevich V.I. Photodynamic therapy in the treatment of extramammary Paget disease // Biomedical Photonics. – 2022. – Vol. 11(3). – Р. 24-34. doi: 10.24931/2413–9432–2022–11-3-24–34Gilyadova A.V., Romanko Yu.S., Ishchenko A.A., Samoilova S.V., Shiryaev A.A., Alekseeva P.M., Efendiev K.T., Reshetov I.V. Photodynamic therapy for precancer diseases and cervical cancer (review of literature). Biomedical Photonics, 2021, vol. 10(4), рр. 59-67. doi: 10.24931/2413–9432–2021–10-4-59-67Gilyadova A.V., Romanko Yu.S., Ishchenko A.A., Samoilova S.V., Shiryaev A.A., Alekseeva P.M., Efendiev K.T., Reshetov I.V. Photodynamic therapy for precancer diseases and cervical cancer (review of literature) // Biomedical Photonics. – 2021. – Vol. 10(4). – Р. 59-67. doi: 10.24931/2413–9432–2021–10-4-59-67Filonenko E.V., Ivanova-Radkevich V.I. Photodynamic therapy in the treatment of patients with mycosis fungoides. Biomedical Photonics, 2022, vol. 11(1). рр. 27-36. doi: 10.24931/2413–9432–2022–11-1-27-37Filonenko E.V., Ivanova-Radkevich V.I. Photodynamic therapy in the treatment of patients with mycosis fungoides // Biomedical Photonics. – 2022. – Vol. 11(1). – P. 27-36. doi: 10.24931/2413–9432–2022–11-1-27-37

The authors declare that there are no conflicts of interest present.